Investigational New Drugs

, Volume 15, Issue 1, pp 5–13

The preclinical evaluation of angiogenesis inhibitors

Authors

  • Michael S. O'Reilly
    • Department of SurgeryChildren's Hospital
    • Department of Cellular BiologyHarvard Medical School
Article

DOI: 10.1023/A:1005762410476

Cite this article as:
O'Reilly, M.S. Invest New Drugs (1997) 15: 5. doi:10.1023/A:1005762410476

Abstract

Angiogenesis is a fundamental process which is required for a number of physiological and pathophysiological processes. The field of angiogenesis therefore has many therapeutic implications and has progressed rapidly. Many strategies have been devised to regulate angiogenesis and several endogenous and synthetic inhibitors of angiogenesis have now been identified. These inhibitors can be used to treat a number of angiogenesis-dependent diseases and they offer a novel means of potently inhibiting tumor growth without significant toxicity or drug resistance. Recently, some of these inhibitors have entered clinical trials. In this article, I will review methods currently employed in the preclinical evaluation of angiogenesis inhibitors and I will discuss some of the implications of angiogenesis research.

angiogenesisinhibitorsanimal modelsendothelial cellscarcinomametastasis

Copyright information

© Kluwer Academic Publishers 1997